AI-engineered nano-vaccines to counter antimicrobial resistance in immunosuppressed and oncologic populations

Antimicrobial resistance (AMR) remains one of the most pressing post-pandemic threats, particularly in immunosuppressed and oncologic populations where immune dysfunction and broad-spectrum antibiotic exposure converge. Globally, more than 1.27 million deaths each year are directly attributed to AMR, with resistant infections affecting nearly half of hospitalized cancer patients. Traditional antibiotic stewardship has proven insufficient, prompting exploration of AI-engineered nano-vaccines as an innovative prophylactic solution. These platforms integrate artificial intelligence for antigen prediction with nanoparticle-based delivery to stimulate targeted immunity even in compromised hosts. Preclinical studies demonstrate over 90% accuracy in epitope mapping and up to a 12-fold increase in antibody titers compared to conventional vaccines. Early translational trials in post-chemotherapy cohorts show a 60% reduction in resistant bacterial colonization, highlighting their preventive potential. AI-driven nano-immunization represents a transformative strategy to restore antimicrobial protection in high-risk patient populations and mitigate the expanding global AMR crisis.